RIGEL PHARMACEUTICALS, INC. Restructuring Charges
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Restructuring Charges of $1.32 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2025-03-04
- RIGEL PHARMACEUTICALS, INC. restructuring charges for the quarter ending 2016-12-31 was $0.00.
- RIGEL PHARMACEUTICALS, INC. restructuring charges for the quarter ending 2016-09-30 was $5.77M.
- RIGEL PHARMACEUTICALS, INC. restructuring charges for the quarter ending 2013-12-31 was $0.00.
- RIGEL PHARMACEUTICALS, INC. restructuring charges for the quarter ending 2013-09-30 was $1.70M.
- RIGEL PHARMACEUTICALS, INC. restructuring charges for fiscal 2022 was $1.32M, a 62.51% decline from fiscal 2021.
- RIGEL PHARMACEUTICALS, INC. restructuring charges for fiscal 2021 was $3.52M.
- RIGEL PHARMACEUTICALS, INC. restructuring charges for fiscal 2016 was $5.77M.
- RIGEL PHARMACEUTICALS, INC. restructuring charges for fiscal 2013 was $1.68M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 3 month as first filed | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $1.32M 10-K · filed 2025-03-04 | ||||
| 2021-12-31 | $3.52M 10-K · filed 2024-03-05 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $5.77M derived: sum of 2 quarters · filed 2019-02-28 | $5.77M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $5.77M 10-Q · filed 2017-11-07 | $5.77M 10-Q · filed 2017-11-07 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $1.70M derived: sum of 2 quarters · filed 2016-03-08 | $1.68M 10-K · filed 2016-03-08 | ||
| 2013-09-30 | $1.70M 10-K · filed 2015-03-03 | $1.68M 10-Q · filed 2013-11-05 | $1.68M 10-Q · filed 2014-11-04 | ||
| 2011-12-31 | $0.00 10-K · filed 2012-03-06 | ||||
| 2010-12-31 | $0.00 10-K · filed 2012-03-06 | ||||
| 2009-12-31 | $1.14M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |